<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01031407</url>
  </required_header>
  <id_info>
    <org_study_id>100027</org_study_id>
    <secondary_id>10-M-0027</secondary_id>
    <nct_id>NCT01031407</nct_id>
  </id_info>
  <brief_title>Cognitive Neuroscience of Autism Spectrum Disorders</brief_title>
  <official_title>Cognitive Neuroscience of Autism Spectrum Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

        -  Autism spectrum disorders (ASDs) are a group of developmental disorders that affect
           communication, social interaction, and behavior. Relatively little is known about the
           relationship between genetics and behavior among these individuals and their close
           relatives. Researchers are interested in using interviews and rating scales to better
           understand these issues, as well as collecting brain scan data and genetic samples for
           testing and comparison.

        -  By comparing test results and genetic samples from healthy volunteers, people with ASD,
           and parents (or caregivers or legal guardians) of the first two groups, researchers hope
           to better understand the neuroscience of ASD.

      Objectives:

        -  To learn more about the brain in healthy people and in people with autism spectrum
           disorders.

        -  To study genes that might be involved in autism spectrum disorders by collecting DNA
           samples from participants.

      Eligibility:

      The following groups of participants will be eligible for the study:

        -  Individuals between 5 and 89 years of age who have autism spectrum disorders.

        -  Healthy volunteers between 5 and 89 years of age.

        -  Cognitively impaired children between 5 and 17 years of age.

        -  Parents/caregivers/legal guardians of individuals in the above three groups.

      Design:

        -  Participants will visit the National Institutes of Health Clinical Center for research
           tests, which will be administered over multiple visits. Researchers will determine the
           specific tests to be administered based on the medical history of the study participant.

        -  Researchers will study the brain through interviews, tests of thinking and memory
           (neuropsychological tests), brain imaging with magnetic resonance imaging (MRI), and
           magnetoencephalography (MEG).

        -  The study will also collect blood or saliva to obtain a DNA sample.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: The primary objective of the proposed studies is to utilize neuroimaging
      (functional Magnetic Resonance Imaging [fMRI], structural MRI [sMRI], Magnetoencephalography
      [MEG]) and neuropsychological tools (eye-tracking, cognitive experiments, clinical
      neuropsychological measures, questionnaires, etc.) to identify cognitive idiosyncrasies
      (e.g., social-cognitive deficits, visual perceptual assets, and savant skills) characteristic
      of individuals on the autism spectrum and their neural underpinnings across childhood and
      adulthood.

      Study Population: Children, adolescents, and adults with autism spectrum disorders (ASDs),
      controls (i.e., typically developing children, adolescents, and adults and those with mild to
      moderate mental retardation), as well as caregivers/legal guardians/parents of these
      individuals.

      Design: Descriptive/Characterization/Observational studies using primarily neuropsychological
      and neuroimaging methodologies.

      Outcome Measures: Behavioral (reaction time, accuracy, eye movements, etc.) and neuroimaging
      (brain morphometry, BOLD, electrophysiology, etc.).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 19, 2009</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Group differences in brain structure, brain function, and cognitive functions, as well as their genetic associations.</measure>
  </primary_outcome>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Asperger's Disorder</condition>
  <condition>Mental Retardation</condition>
  <condition>Children</condition>
  <condition>Adult</condition>
  <condition>Autism Spectrum Disorders</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Subjects will include:

          1. males and females.

          2. 5-89 years of age.

          3. A minimum IQ of 70 if age 18 or older.

          4. A minimum IQ of 50 if 5-17 years old.

        Inclusion criteria for cognitively impaired children without ASD, Subjects will include:

          1. males and females.

          2. 5-17 years of age IQ of 50-69.

        Subjects in the ASD group will:

          1. meet DSM-IV criteria for one of the pervasive developmental disorders (i.e., autistic
             disorder, Asperger disorder, or pervasive developmental disorder-not otherwise
             specified).

          2. meet or pass the autism cut-off score for social symptoms on the ADI and/or the ASD
             cut-off score from social+communication symptoms on the ADOS.

          3. be able to provide their own consent (for adults).

        EXCLUSION CRITERIA:

        All subjects, except for savants, also will be excluded if they have:

          1. a history of neurological insult/injury.

          2. substantial prenatal drug exposure known to affect later brain and behavior (e.g.,
             cocaine, alcohol).

          3. severely premature birth or birth trauma.

          4. severe medical disorder (e.g., neurofibromatosis, hydrocephalus, cerebral palsy,
             uncontrollable seizure disorder).

          5. a known genetic disorder (e.g., Fragile X or Down syndrome) that would be expected to
             significantly impact findings from cognitive testing and/or neuroimaging.

             Furthermore, subjects will be excluded from MRI/MEG studies, if they have:

          6. any exclusion from MRI scanning including: the presence of metal in their body, having
             a pacemaker, and/or females who are pregnant.

        Exclusion criteria for cognitively impaired children:

          1. An IQ of less than 50

          2. Had severely premature birth or birth trauma,

          3. Typically developing but takes psychiatric medication.

        Healthy volunteers, except for parents of individuals with autism spectrum disorders,
        parents of healthy volunteers, and parents of children with cognitive impairments, will
        also be excluded if they have:

        1. a current or past history of axis I psychiatric conditions or any current usage of
        psychiatric medication.

        Savants have less restrictive exclusionary criteria because: 1) they are a very rare group,
        thus we don t want to limit recruitment further and 2) we can examine common and unique
        cognitive mechanisms across savants, a question of keen interest, regardless of
        co-morbidities. Those with tumors or other neuroimaging-relevant contraindications will be
        excluded from fMRI/MEG procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Martin, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health (NIMH)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelsey D Csumitta</last_name>
    <phone>(301) 435-4928</phone>
    <email>kelsey.csumitta@nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alex Martin, Ph.D.</last_name>
    <phone>(301) 435-1926</phone>
    <email>alexmartin@mail.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2010-M-0027.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Adolphs R. The neurobiology of social cognition. Curr Opin Neurobiol. 2001 Apr;11(2):231-9. Review.</citation>
    <PMID>11301245</PMID>
  </reference>
  <reference>
    <citation>Alarc√≥n M, Yonan AL, Gilliam TC, Cantor RM, Geschwind DH. Quantitative genome scan and Ordered-Subsets Analysis of autism endophenotypes support language QTLs. Mol Psychiatry. 2005 Aug;10(8):747-57.</citation>
    <PMID>15824743</PMID>
  </reference>
  <reference>
    <citation>Baharloo S, Johnston PA, Service SK, Gitschier J, Freimer NB. Absolute pitch: an approach for identification of genetic and nongenetic components. Am J Hum Genet. 1998 Feb;62(2):224-31.</citation>
    <PMID>9463312</PMID>
  </reference>
  <verification_date>March 14, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2009</study_first_submitted>
  <study_first_submitted_qc>December 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2009</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adolescents and Adults</keyword>
  <keyword>Autism</keyword>
  <keyword>Functional Magnetic Resonance Imaging (fMRI)</keyword>
  <keyword>MEG</keyword>
  <keyword>Structural MRI</keyword>
  <keyword>HV</keyword>
  <keyword>Autism Spectrum Disorder</keyword>
  <keyword>ASD</keyword>
  <keyword>Autistic Disorder</keyword>
  <keyword>Asperger Syndrome</keyword>
  <keyword>Mental Retardation</keyword>
  <keyword>Healthy Volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
    <mesh_term>Intellectual Disability</mesh_term>
    <mesh_term>Asperger Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

